Novome Biotechnologies
Latest round
- Series B
Last raised
- Sep 2022
Total raised
- $77M
Investors
- 10
About Novome Biotechnologies
Novome Biotechnologies, Inc.Founded in 2016 and headquartered in San Francisco, US, Novome Biotechnologies, Inc. specializes in engineered microbial therapies. The company has undergone a strategic evolution to refine its focus on personalized medicine. The founding team includes Liz Shepherd, Will DeLoache, and Zachary Russ, with Blake Wise serving as CEO.Novome Bio focuses on the development and commercialization of innovative therapies in the field of microbiome modulation. Their core product offerings revolve around engineered microbial therapies designed to treat various gastrointestinal and metabolic disorders. These therapies utilize advanced genetic engineering techniques to create specific strains of bacteria that can target and rectify dysfunctional metabolic pathways. The end-use cases primarily center around improving patient outcomes in disorders such as obesity and type 2 diabetes, with a keen emphasis on personalized medicine.Novome Bio generates revenue through a combination of direct-to-consumer sales and partnerships with healthcare providers and research institutions. The company engages in subscription-based models for access to their proprietary therapies, offering a structured approach that allows clients to utilize their products over a defined period. Transactions typically occur through healthcare networks, where Novome Bio collaborates with clinics and hospitals to integrate their products into treatment plans.In September 2022, Novome Biotechnologies, Inc. The company plans to enhance its product offerings further and is evaluating opportunities to expand into additional health markets across North America and Europe.
Who invested in Novome Biotechnologies
10 investors across 2 rounds
See all investors in Novome Biotechnologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Novome Biotechnologies
Who invested in Novome Biotechnologies?
Novome Biotechnologies has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Novome Biotechnologies raised?
Novome Biotechnologies has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Novome Biotechnologies last raise money?
Novome Biotechnologies's most recent round on record is a Series B, in Sep 2022.
What does Novome Biotechnologies do?
Novome Biotechnologies is a biotechnology company.
Where is Novome Biotechnologies headquartered?
Novome Biotechnologies is headquartered in San Francisco, US.
Which VCs invest in companies like Novome Biotechnologies?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Novome Biotechnologies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Novome Biotechnologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.